Study identification

PURI

https://redirect.ema.europa.eu/resource/40302

EU PAS number

EUPAS33865

Study ID

40302

Official title and acronym

A Real World Evidence prospective cohort study in the management of metastatic colorectal cancer: a clinical and patient perspective (PROMETCO)

DARWIN EU® study

No

Study countries

Argentina
Austria
Belgium
Croatia
Czechia
France
Germany
Greece
Hungary
Ireland
Italy
Netherlands
Portugal
Slovenia
Spain
Sweden
Switzerland
United Kingdom

Study description

This is an observationnal study to describe the following for mCRC patients in a real world setting: - Overall survival - Treatment patterns for mCRC throughout the continuum of care Effectiveness/safety of treatments - Reasons for therapy discontinuations and choice of subsequent treatment - Adherence to National and European Society for Medical Oncology (ESMO) Guidelines - Healthcare resource utilization - Patient reported outcomes

Study status

Ongoing
Research institution and networks

Institutions

Contact details

Miriam Koopman

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Data collection

Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Servier
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)